News / Taiwan / economic_daily
Taiho Oncology's BEQIA Enters FDA Review, Targeting Q2 Approval
Health Technology · Pharmaceuticals: Major · economic_daily · 2026-08-23
6467
Taiho Oncology's novel anti-thrombotic oral film BEQIA has entered formal FDA review, with potential approval expected by Q2 next year to capture a massive market.
What Happened
Regulatory Progress: Taiho Oncology's anti-thrombotic oral film, BEQIA (TAH3311), has officially entered the substantive review phase with the U.S. FDA as of August 21. The company resubmitted its New Drug Application in June, successfully clearing the initial administrative hurdles.
Market Potential: Under the Prescription Drug User Fee Act, the company anticipates receiving U.S. regulatory approval by the second quarter of next year. As the world's first Apixaban oral film developed via advanced transdermal technology, it targets a multi-billion dollar market.
Technological Edge: BEQIA utilizes proprietary drug delivery technology to provide a more convenient administration method for patients. Taiho Oncology is leveraging this innovation to establish a strong foothold in the global anti-thrombotic therapeutic space.
Future Outlook: With the formal review underway, the company remains focused on navigating the final stages of the approval process. Management views this drug as a key pillar for future growth and commercial success in the international market.